Hematological	B:C0243095
,	O
biochemical	O
,	O
and	O
toxicopathic	O
effects	I:C0243095
of	O
subchronic	O
acetamiprid	O
toxicity	O
in	O
Wistar	O
rats	I:C0034716
.	O

Hematological	O
,	O
biochemical	B:C0243095
,	O
and	O
toxicopathic	O
effects	I:C0243095
of	O
subchronic	O
acetamiprid	O
toxicity	O
in	O
Wistar	O
rats	I:C0034716
.	O

Hematological	O
,	O
biochemical	O
,	O
and	O
toxicopathic	B:C0243095
effects	I:C0243095
of	O
subchronic	O
acetamiprid	O
toxicity	O
in	O
Wistar	O
rats	I:C0034716
.	O

Hematological	O
,	O
biochemical	O
,	O
and	O
toxicopathic	O
effects	I:C0243095
of	O
subchronic	O
acetamiprid	B:C1142891
toxicity	O
in	O
Wistar	O
rats	I:C0034716
.	O

Hematological	O
,	O
biochemical	O
,	O
and	O
toxicopathic	O
effects	I:C0243095
of	O
subchronic	O
acetamiprid	O
toxicity	B:C0600688
in	O
Wistar	O
rats	I:C0034716
.	O

Hematological	O
,	O
biochemical	O
,	O
and	O
toxicopathic	O
effects	I:C0243095
of	O
subchronic	O
acetamiprid	O
toxicity	O
in	O
Wistar	B:C0034716
rats	I:C0034716
.	O

Acetamiprid	B:C1142891
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
neonicotinoids	O
.	O

Acetamiprid	O
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
neonicotinoids	B:C1997222
.	O

This	O
study	O
investigates	O
toxic	B:C0600688
effects	I:C0600688
of	O
repeated	O
oral	O
administration	O
of	O
three	O
doses	O
of	O
acetamiprid	O
(	O
1/20	O
,	O
1/10	O
,	O
and	O
1/5	O
of	O
LD50	O
)	O
during	O
60	O
days	O
.	O

This	O
study	O
investigates	O
toxic	O
effects	I:C0600688
of	O
repeated	O
oral	O
administration	O
of	O
three	O
doses	O
of	O
acetamiprid	B:C1142891
(	O
1/20	O
,	O
1/10	O
,	O
and	O
1/5	O
of	O
LD50	O
)	O
during	O
60	O
days	O
.	O

For	O
this	O
,	O
male	O
Wistar	B:C0034716
rats	I:C0034716
were	O
divided	O
into	O
four	O
different	O
groups	O
.	O

Hematological	B:C0243095
,	O
biochemical	O
,	O
and	O
toxicopathic	O
effects	I:C0243095
of	O
acetamiprid	O
were	O
evaluated	O
.	O

Hematological	O
,	O
biochemical	B:C0243095
,	O
and	O
toxicopathic	O
effects	I:C0243095
of	O
acetamiprid	O
were	O
evaluated	O
.	O

Hematological	O
,	O
biochemical	O
,	O
and	O
toxicopathic	B:C0243095
effects	I:C0243095
of	O
acetamiprid	O
were	O
evaluated	O
.	O

Hematological	O
,	O
biochemical	O
,	O
and	O
toxicopathic	O
effects	I:C0243095
of	O
acetamiprid	B:C1142891
were	O
evaluated	O
.	O

Hematological	O
,	O
biochemical	O
,	O
and	O
toxicopathic	O
effects	I:C0243095
of	O
acetamiprid	O
were	O
evaluated	B:C0220825
.	O

According	O
to	O
the	O
results	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
body	B:C0043094
weight	I:C0043094
gain	I:C0043094
at	O
the	O
highest	O
dose	O
1/5	O
of	O
LD50	O
of	O
acetamiprid	O
was	O
noticed	O
.	O

According	O
to	O
the	O
results	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
body	O
weight	I:C0043094
gain	I:C0043094
at	O
the	O
highest	O
dose	O
1/5	O
of	O
LD50	O
of	O
acetamiprid	B:C1142891
was	O
noticed	O
.	O

An	O
increase	O
in	O
the	O
relative	O
liver	B:C0023884
weight	O
was	O
also	O
observed	O
at	O
this	O
dose	O
level	O
.	O

A	O
significant	O
decrease	O
in	O
RBC	B:C0014792
,	O
HGB	O
,	O
and	O
HCT	O
in	O
rats	O
treated	O
with	O
higher	O
doses	O
of	O
acetamiprid	O
(	O
1/10	O
and	O
1/5	O
of	O
LD50	O
)	O
was	O
noted	O
.	O

A	O
significant	O
decrease	O
in	O
RBC	O
,	O
HGB	B:C0019046
,	O
and	O
HCT	O
in	O
rats	O
treated	O
with	O
higher	O
doses	O
of	O
acetamiprid	O
(	O
1/10	O
and	O
1/5	O
of	O
LD50	O
)	O
was	O
noted	O
.	O

A	O
significant	O
decrease	O
in	O
RBC	O
,	O
HGB	O
,	O
and	O
HCT	B:C0518014
in	O
rats	O
treated	O
with	O
higher	O
doses	O
of	O
acetamiprid	O
(	O
1/10	O
and	O
1/5	O
of	O
LD50	O
)	O
was	O
noted	O
.	O

A	O
significant	O
decrease	O
in	O
RBC	O
,	O
HGB	O
,	O
and	O
HCT	O
in	O
rats	B:C0034716
treated	O
with	O
higher	O
doses	O
of	O
acetamiprid	O
(	O
1/10	O
and	O
1/5	O
of	O
LD50	O
)	O
was	O
noted	O
.	O

A	O
significant	O
decrease	O
in	O
RBC	O
,	O
HGB	O
,	O
and	O
HCT	O
in	O
rats	O
treated	O
with	O
higher	O
doses	O
of	O
acetamiprid	B:C1142891
(	O
1/10	O
and	O
1/5	O
of	O
LD50	O
)	O
was	O
noted	O
.	O

However	O
,	O
a	O
significant	O
increase	O
in	O
WBC	B:C0023516
and	O
PLT	O
were	O
observed	O
at	O
the	O
same	O
doses	O
.	O

However	O
,	O
a	O
significant	O
increase	O
in	O
WBC	O
and	O
PLT	B:C0005821
were	O
observed	O
at	O
the	O
same	O
doses	O
.	O

Furthermore	O
,	O
acetamiprid	B:C1142891
induced	O
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	O
aminotransferase	I:C0004002
(	O
aspartate	O
aminotransferase	I:C0004002
)	O
,	O
alanine	O
aminotransferase	I:C0001899
(	O
alanine	O
aminotransferase	I:C0001899
)	O
,	O
alkaline	O
phosphates	I:C0002059
(	O
alkaline	O
phosphates	I:C0002059
)	O
,	O
and	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	O
damage	I:C0151763
.	O

Furthermore	O
,	O
acetamiprid	O
induced	B:C4279912
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	O
aminotransferase	I:C0004002
(	O
aspartate	O
aminotransferase	I:C0004002
)	O
,	O
alanine	O
aminotransferase	I:C0001899
(	O
alanine	O
aminotransferase	I:C0001899
)	O
,	O
alkaline	O
phosphates	I:C0002059
(	O
alkaline	O
phosphates	I:C0002059
)	O
,	O
and	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	O
damage	I:C0151763
.	O

Furthermore	O
,	O
acetamiprid	O
induced	O
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	B:C0243102
of	O
aspartate	O
aminotransferase	I:C0004002
(	O
aspartate	O
aminotransferase	I:C0004002
)	O
,	O
alanine	O
aminotransferase	I:C0001899
(	O
alanine	O
aminotransferase	I:C0001899
)	O
,	O
alkaline	O
phosphates	I:C0002059
(	O
alkaline	O
phosphates	I:C0002059
)	O
,	O
and	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	O
damage	I:C0151763
.	O

Furthermore	O
,	O
acetamiprid	O
induced	O
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	B:C0004002
aminotransferase	I:C0004002
(	O
aspartate	O
aminotransferase	I:C0004002
)	O
,	O
alanine	O
aminotransferase	I:C0001899
(	O
alanine	O
aminotransferase	I:C0001899
)	O
,	O
alkaline	O
phosphates	I:C0002059
(	O
alkaline	O
phosphates	I:C0002059
)	O
,	O
and	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	O
damage	I:C0151763
.	O

Furthermore	O
,	O
acetamiprid	O
induced	O
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	O
aminotransferase	I:C0004002
(	O
aspartate	B:C0004002
aminotransferase	I:C0004002
)	O
,	O
alanine	O
aminotransferase	I:C0001899
(	O
alanine	O
aminotransferase	I:C0001899
)	O
,	O
alkaline	O
phosphates	I:C0002059
(	O
alkaline	O
phosphates	I:C0002059
)	O
,	O
and	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	O
damage	I:C0151763
.	O

Furthermore	O
,	O
acetamiprid	O
induced	O
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	O
aminotransferase	I:C0004002
(	O
aspartate	O
aminotransferase	I:C0004002
)	O
,	O
alanine	B:C0001899
aminotransferase	I:C0001899
(	O
alanine	O
aminotransferase	I:C0001899
)	O
,	O
alkaline	O
phosphates	I:C0002059
(	O
alkaline	O
phosphates	I:C0002059
)	O
,	O
and	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	O
damage	I:C0151763
.	O

Furthermore	O
,	O
acetamiprid	O
induced	O
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	O
aminotransferase	I:C0004002
(	O
aspartate	O
aminotransferase	I:C0004002
)	O
,	O
alanine	O
aminotransferase	I:C0001899
(	O
alanine	B:C0001899
aminotransferase	I:C0001899
)	O
,	O
alkaline	O
phosphates	I:C0002059
(	O
alkaline	O
phosphates	I:C0002059
)	O
,	O
and	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	O
damage	I:C0151763
.	O

Furthermore	O
,	O
acetamiprid	O
induced	O
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	O
aminotransferase	I:C0004002
(	O
aspartate	O
aminotransferase	I:C0004002
)	O
,	O
alanine	O
aminotransferase	I:C0001899
(	O
alanine	O
aminotransferase	I:C0001899
)	O
,	O
alkaline	B:C0002059
phosphates	I:C0002059
(	O
alkaline	O
phosphates	I:C0002059
)	O
,	O
and	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	O
damage	I:C0151763
.	O

Furthermore	O
,	O
acetamiprid	O
induced	O
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	O
aminotransferase	I:C0004002
(	O
aspartate	O
aminotransferase	I:C0004002
)	O
,	O
alanine	O
aminotransferase	I:C0001899
(	O
alanine	O
aminotransferase	I:C0001899
)	O
,	O
alkaline	O
phosphates	I:C0002059
(	O
alkaline	B:C0002059
phosphates	I:C0002059
)	O
,	O
and	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	O
damage	I:C0151763
.	O

Furthermore	O
,	O
acetamiprid	O
induced	O
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	O
aminotransferase	I:C0004002
(	O
aspartate	O
aminotransferase	I:C0004002
)	O
,	O
alanine	O
aminotransferase	I:C0001899
(	O
alanine	O
aminotransferase	I:C0001899
)	O
,	O
alkaline	O
phosphates	I:C0002059
(	O
alkaline	O
phosphates	I:C0002059
)	O
,	O
and	O
lactate	B:C0022917
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	O
damage	I:C0151763
.	O

Furthermore	O
,	O
acetamiprid	O
induced	O
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	O
aminotransferase	I:C0004002
(	O
aspartate	O
aminotransferase	I:C0004002
)	O
,	O
alanine	O
aminotransferase	I:C0001899
(	O
alanine	O
aminotransferase	I:C0001899
)	O
,	O
alkaline	O
phosphates	I:C0002059
(	O
alkaline	O
phosphates	I:C0002059
)	O
,	O
and	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	B:C0022917
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	O
damage	I:C0151763
.	O

Furthermore	O
,	O
acetamiprid	O
induced	O
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	O
aminotransferase	I:C0004002
(	O
aspartate	O
aminotransferase	I:C0004002
)	O
,	O
alanine	O
aminotransferase	I:C0001899
(	O
alanine	O
aminotransferase	I:C0001899
)	O
,	O
alkaline	O
phosphates	I:C0002059
(	O
alkaline	O
phosphates	I:C0002059
)	O
,	O
and	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	B:C2331083
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	O
damage	I:C0151763
.	O

Furthermore	O
,	O
acetamiprid	O
induced	O
liver	I:C4279912
toxicity	I:C4279912
measured	O
by	O
the	O
increased	O
activities	O
of	O
aspartate	O
aminotransferase	I:C0004002
(	O
aspartate	O
aminotransferase	I:C0004002
)	O
,	O
alanine	O
aminotransferase	I:C0001899
(	O
alanine	O
aminotransferase	I:C0001899
)	O
,	O
alkaline	O
phosphates	I:C0002059
(	O
alkaline	O
phosphates	I:C0002059
)	O
,	O
and	O
lactate	O
dehydrogenase	I:C0022917
(	O
lactate	O
dehydrogenase	I:C0022917
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	O
membrane	I:C2331083
architecture	I:C2331083
and	O
hepatocellular	B:C0151763
damage	I:C0151763
.	O

In	O
addition	O
,	O
exposure	O
to	O
acetamiprid	B:C1142891
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	O
activities	O
(	O
p	O
≤	O
0.01	O
)	O
with	O
concomitant	O
increase	O
in	O
lipid	O
peroxidation	I:C0023775
in	O
rat	O
liver	O
.	O

In	O
addition	O
,	O
exposure	O
to	O
acetamiprid	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
superoxide	B:C0038838
dismutase	I:C0038838
and	O
catalase	O
activities	O
(	O
p	O
≤	O
0.01	O
)	O
with	O
concomitant	O
increase	O
in	O
lipid	O
peroxidation	I:C0023775
in	O
rat	O
liver	O
.	O

In	O
addition	O
,	O
exposure	O
to	O
acetamiprid	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	B:C0007367
activities	O
(	O
p	O
≤	O
0.01	O
)	O
with	O
concomitant	O
increase	O
in	O
lipid	O
peroxidation	I:C0023775
in	O
rat	O
liver	O
.	O

In	O
addition	O
,	O
exposure	O
to	O
acetamiprid	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	O
activities	B:C0243102
(	O
p	O
≤	O
0.01	O
)	O
with	O
concomitant	O
increase	O
in	O
lipid	O
peroxidation	I:C0023775
in	O
rat	O
liver	O
.	O

In	O
addition	O
,	O
exposure	O
to	O
acetamiprid	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	O
activities	O
(	O
p	O
≤	O
0.01	O
)	O
with	O
concomitant	O
increase	O
in	O
lipid	B:C0023775
peroxidation	I:C0023775
in	O
rat	O
liver	O
.	O

In	O
addition	O
,	O
exposure	O
to	O
acetamiprid	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	O
activities	O
(	O
p	O
≤	O
0.01	O
)	O
with	O
concomitant	O
increase	O
in	O
lipid	O
peroxidation	I:C0023775
in	O
rat	B:C0034716
liver	O
.	O

In	O
addition	O
,	O
exposure	O
to	O
acetamiprid	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
superoxide	O
dismutase	I:C0038838
and	O
catalase	O
activities	O
(	O
p	O
≤	O
0.01	O
)	O
with	O
concomitant	O
increase	O
in	O
lipid	O
peroxidation	I:C0023775
in	O
rat	O
liver	B:C0023884
.	O

These	O
findings	B:C0243095
highlight	O
the	O
subchronic	O
hepatotoxicity	O
of	O
acetamiprid	O
.	O

These	O
findings	O
highlight	O
the	O
subchronic	O
hepatotoxicity	B:C0235378
of	O
acetamiprid	O
.	O

These	O
findings	O
highlight	O
the	O
subchronic	O
hepatotoxicity	O
of	O
acetamiprid	B:C1142891
.	O

